

JLW

TRANSMITTAL FORM

(to be used for all correspondence after initial filing)

		Application Number	10/718,077
		Filing Date	11/20/03
		First Named Inventor	Corvari
		Art Unit	1617
		Examiner Name	T. Criares
Total Number of Pages in This Submission	590	Attorney Docket Number	CP185B

ENCLOSURES (check all that apply)

<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input type="checkbox"/> Amendment / Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input checked="" type="checkbox"/> Information Disclosure Statement <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Response to Missing Parts/ Incomplete Application <input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s) _____	<input type="checkbox"/> After Allowance Communication to Technology Center (TC) <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Other Enclosure(s) (please identify below): 1449 & 18 References Copy of International Search Report
Remarks		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm or Individual name	Eric K. Voelk, Registration No. 45,185
Signature	
Date	September 15, 2004

CERTIFICATE OF TRANSMISSION/MAILING

I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below.

Typed or printed name	Maureen K. Fitzpatrick		
Signature		Date	September 15, 2004

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 1.12 and 37 CFR 1.14. This collection is estimated to 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.



Attorney Docket No.: CP185B

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re Application of: Dickason et al.

Serial No.: 10/718,077

Group Art Unit.: 1617

Filing Date: November 20, 2003


Examiner: T. Criares

For.: PARTICLE-FORMING COMPOSITIONS CONTAINING FUSED
PYRROLOCARBAZOLES

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

DATE OF DEPOSIT: September 15, 2004
I HEREBY CERTIFY THAT THIS PAPER IS BEING
DEPOSITED WITH THE UNITED STATES POSTAL SERVICE
AS FIRST CLASS MAIL, POSTAGE PREPAID ON THE DATE
INDICATED ABOVE AND IS ADDRESSED TO THE
COMMISSIONER FOR PATENTS, P.O. BOX 1450,
ALEXANDRIA, VA 22313-1450.



Maureen K. Fitzpatrick

INFORMATION DISCLOSURE STATEMENT

Pursuant to 37 C.F.R. §1.56 and in accordance with 37 C.F.R. §§1.97-1.98, information relating to the above-identified application is hereby disclosed. Inclusion of information in this statement is not to be construed as a representation that a search has been made or an admission that this information is material to the patentability as defined in 37 C.F.R. § 1.56(b).

In accordance with §1.97(b), since this Information Disclosure Statement is being filed either within three months of the filing date of the above-identified application, within three months of the date of entry into the national stage of the above-identified application as set forth in § 1.491, or before the mailing date of a first Office Action on the merits of the above-identified application. No additional fee is required.

A copy of each cited non-US patent reference is enclosed.

Please charge any deficiency or credit any overpayment to Deposit Account No. 03-1195.

Date: September 15, 2004



Eric K. Voelk
Attorney for Applicant
Registration No. 45,185

CEPHALON, Inc.
145 Brandywine Parkway
West Chester, PA 19380
Telephone: (610) 738-6465
Facsimile: (610) 738-6590

FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT BY APPLICANT List of Patent and Publications Cited by Applicant		Attorney Docket	
		CP185B	
		Application Number	
		10/718,077	
		Filing Date	
		11/20/03	
First Named Inventor			
Corvari			
Group Art Unit			
1614			
Examiner Name			
Unknown			
Sheet		1 of 2	

U.S. PATENT DOCUMENTS						
Examiner Initials	Cite No.	Document Number	Name	Date of Publication	Class	Subclass
	A1	4,877,776	Murkata et al.	10/31/1989		
	A2	4,923,986	Murkata et al.	05/8/1990		
	A3	5,043,335	Kleinschrothe et al.	08/27/1991		
	A4	5,093,330	Caravatti et al.	03/03/1992		
	A5	5,242,932	Gandy et al.	09/07/1993		
	A6	5,461,146	Lewis et al.	10/24/1995		
	A7	5,468,872	Glicksman et al.	11/21/1995		
	A8	5,475,110	Hudkins et al.	12/12/1995		
	A9	5,516,771	Dionne et al.	05/14/1996		
	A10	5,591,855	Hudkins et al.	01/07/1997		
	A11	5,594,009	Hudkins et al.	01/14/1997		
	A12	5,599,808	Goldstein et al.	02/04/1997		
	A13	5,616,724	Hudkins et al.	04/01/1997		
	A14	5,621,100	Lewis et al.	04/15/1997		
	A15	5,621,101	Lewis et al.	04/15/1997		
	A16	5,658,898	Weder et al.	08/19/1997		
	A17	5,705,511	Hudkins et al.	01/06/1998		
	A18	5,726,164	Weder et al.	03/10/1998		
	A19	5,801,190	Hudkins et al.	09/01/1998		
	A20	6,200,968	Dickason et al.	03/13/2001		

FOREIGN PATENT DOCUMENTS					
Examiner Initials	Cite No.	Document No.	Date	Country	Translation YES NO
	B1	0 657 164	06/14/1995	EP	
	B2	0 850 646	07/01/1998	EP	
	B3	JP 04-124122	04/24/1992	Japan	**
	B4	JP 62-120388	06/01/1987	Japan	abstract
	B5	JP 62-155284	07/10/1987	Japan	abstract
	B6	JP 62-155285	07/10/1987	Japan	abstract
	B7	JP 63-295588	12/01/1988	Japan	X
	B8	JP 63-295589	12/01/1988	Japan	abstract

Examiner's Signature	Date:
----------------------	-------

**A copy of the International Search Report dated 11/17/99 is attached which indicates the documents considered to be relevant and provides an explanation of the relevance of each reference.

FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT BY APPLICANT List of Patent and Publications Cited by Applicant		Attorney Docket		CP185B
		Application Number		10/718,077
		Filing Date		11/20/03
		First Named Inventor		Corvari
		Group Art Unit		1614
		Examiner Name		Unknown
		Sheet	2 of 2	

	B9	WO 00/48571	08/24/2000	WIPO		
	B10	WO 93/00909	01/21/1993	WIPO		
	B11	WO 93/08809	05/13/1993	WIPO		
	B12	WO 97/46565	12/11/1997	WIPO		

OTHER DOCUMENTS Non-Patent Literature Documents		
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), Title of Article, Title of Journal (book, magazine, catalog, etc.) Date, Pertinent Pages, Volume-Issue Number, publisher, city and/or country where published.
	C1	Berg et al., "K-252a Inhibits Nerve Growth Factor-induced trk Proto-oncogene Tyrosine Phosphorylation and Kinase Activity", <i>J. Biol. Chem.</i> , 1992 , 267, pgs 13-16.
	C2	Kase et al., "K-252 Compounds, Novel and Potent Inhibitors of Protein Kinase C and Cyclic Nucleotide-Dependent Protein Kinases", <i>Biochem. Biophys. Res. Commun.</i> , 1987 , 142, pgs 436-440.
	C3	Moody et al., "Synthesis of the Staurosporine Aglycon", <i>J. Org. Chem.</i> , 1992 , 57, pgs 2105-2114.
	C4	Nakanish et al., "K-252b, c and d, Potent Inhibitors of Protein Kinase C from Microbial Origin", <i>J. Antibiotics</i> , 1986 , 34, pgs 1066-1071.
	C5	Shah et al., "Self-emulsifying drug delivery systems (SEDDS) with polyglycolized glycerides for improving in vitro dissolution and oral absorption of lipophilic drugs", <i>International Journal of Pharmaceutics (Netherlands)</i> , 1994 , 106, pgs 15-23.
	C6	Yamamoto et al., "Enhanced rectal absorption of itazigrel formulated with polysorbate 80 micelle vehicle in rat: role of co-administered esterase", <i>J. Pharm. Pharmacol.</i> , 1994 , 46, pgs 608-611.

Examiner's Signature	Date:
----------------------	-------

**A copy of the International Search Report dated 11/17/99 is attached which indicates the documents considered to be relevant and provides an explanation of the relevance of each reference.